OSR Holdings, Inc. (OSRH): debt financing — Bellevue Life Sciences SPAC gets $1.2M sponsor note, extends deadline to May 14

OSR Holdings, Inc.

Issued $1.2M promissory note to sponsor, unsecured, no interest, due by Dec 31, 2024 or upon business combination.
Sponsor deposited $60,000 into trust to extend business combination deadline from April 15 to May 14, 2024.
Principal forgiven if no business combination occurs by charter deadline; sponsor waives trust account claims.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

OSR Holdings, Inc. incurred loan of $1,200,000 with Bellevue Global Life Sciences Investors, LLC at not interest bearing maturing earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination.

Instrument: loan
Principal: $1,200,000
Counterparty: Bellevue Global Life Sciences Investors, LLC
Rate: not interest bearing
Maturity: earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination
Event: incurrence

Exact text from the filing

On April 8, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $1,200,000 to Bellevue Global Life Sciences Investors, LLC (“ BGLSI ”), the sponsor of the Company. The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination (the “ Maturity Date ” ) .

View on SEC.gov

310 debt financings filed in the last 30 days. Browse all debt financings →

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000898432-24-000311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.